Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Herzog, German Chancellor Merz discuss final Gaza hostage, Arrow 3 exchange in Jerusalem - 2Israeli Chief of Staff declares new border with Gaza Strip
- 3Israel reports first missile fire from Yemen since start of Iran war
- 4People who talk with their hands seem more clear and persuasive – new research
- 5Investigating Inside Plan and Home Style: Change Your Residing Space
- 4 buzzy new TV shows to watch — plus the return of 'The Comeback,' 'Jury Duty' and more
- San Francisco mayor says city in talks to bring pandas back to zoo ahead of trip to Asia
- Why the weirdest sea level changes on Earth are happening off the coast of Japan
- Zelensky confidant dismissed from further posts amid bribery scandal
- UK to hold fresh pork, other affected Spanish products at border amid African swine fever outbreak
- Share your number one city visit transport that leaves a mark on the world wake up!
- Medical team successfully delivers baby and removes massive tumor
- See the moon shine with Saturn in the southern sky after sunset Dec. 26
- 'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
